Recombinant human interferon-gamma in patients with chronic granulomatous disease : European follow up study

This was an uncontrolled, open-label follow up study of a previous 12-month, randomized, double-blind, placebo-controlled trial performed to assess the long-term efficacy and safety of Recombinant Human Interferon Gamma (rIFN-gamma) in patients with chronic granulomatous disease (CGD). In two centre...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pediatrics 1995-04, Vol.154 (4), p.295-298
Main Authors: WEENING, R. S, LEITZ, G. J, SEGER, R. A
Format: Article
Language:English
Subjects:
Adolescent
Adult
Biological and medical sciences
Child
Child, Preschool
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Europe
Female
Follow-Up Studies
Granulomatous Disease, Chronic - therapy
Humans
Immunomodulators
Injections, Subcutaneous
Interferon-gamma - administration & dosage
Interferon-gamma - adverse effects
Long-Term Care
Male
Medical sciences
Netherlands
Pharmacology. Drug treatments
Recombinant Proteins
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This was an uncontrolled, open-label follow up study of a previous 12-month, randomized, double-blind, placebo-controlled trial performed to assess the long-term efficacy and safety of Recombinant Human Interferon Gamma (rIFN-gamma) in patients with chronic granulomatous disease (CGD). In two centres, 28 patients (24 male, 4 female) with a mean age of 16 years (range 3-37) entered the open-label phase. The patients were treated for a mean of 880 days (range 97-1375 days). Visits were scheduled every 180 days and patients completed one to six visits. rIFN-gamma was administered subcutaneously three times weekly at a dose of 0.05 mg per m2. During the open-label phase of the study 12 patients experienced a serious infection requiring hospitalization within 880 days. The median infection-free time was 993 days. No obvious increase of infections over time was seen. Phagocyte superoxide anion production and phagocyte staphylococcal killing were not influenced by therapy. Seven patients were withdrawn from the study, one because of an adverse reaction, three on their own wish and the other three because they changed to another trial. No patient died during the study. Conclusion. Treatment of patients with CGD with intracellular active antibiotics and additional interferon gamma as infection prophylaxis is safe and justified.
ISSN:0340-6199
1432-1076
DOI:10.1007/BF01957365